Recherche avancée
Instruments
Nom | Mnemo | Place boursière | Volume moyen | Cours | Type | |
---|---|---|---|---|---|---|
ELISA OYJ | ELISA | Nasdaq Helsinki +6 Autres | 294 658 | 42,7 EUR | Action | |
ELISA OYJ | EIA | Deutsche Boerse AG | 24 | 42 EUR | ||
ELISA OYJ | 0I8Y | London S.E. | - | 42,65 EUR | ||
ELISA OYJ | EIA | Börse Stuttgart | - | 42,24 EUR | ||
ELISA OYJ | EIA | BOERSE MUENCHEN | - | 42,8 EUR | ||
ELISA OYJ | ELMUF | OTC Markets | 629 | 45,16 USD | ||
ELISA OYJ | EIA | Berne S.E. | - | - CHF | ||
ELISA OYJ | ELMUY | OTC Markets | 27 | 24 USD | Action | |
ELISA OYJ (EI6) - ELA/C2 | Euronext Amsterdam | - | 42,56 EUR | Future | ||
ELISA OYJ (EI6) - ELA/C5 | Euronext Amsterdam | - | 42,18 EUR | Future | ||
ELISA OYJ (EI6) - ELA/C6 | Euronext Amsterdam | - | 42,53 EUR | Future | ||
ELISA OYJ (EI6) - ELA/20241220 | Euronext Amsterdam | - | 42,47 EUR | Future | ||
ELISA OYJ (EI6) - ELA/C1 | Euronext Amsterdam | - | 42,4 EUR | Future | ||
ELISA OYJ (EI6) - ELA/C3 | Euronext Amsterdam | - | 42,64 EUR | Future | ||
ELISA OYJ (EI6) - ELA/C4 | Euronext Amsterdam | - | 42,92 EUR | Future | ||
ELISA OYJ (EI6) - ELA/20240620 | Euronext Amsterdam | - | 42,8 EUR | Future |
Profils Sociétés (17)
Beijing Wantai Biopharmaceutical Co. est une société principalement engagée dans la recherche et le développement, la production et la vente de diagnostics in-vitro. La société produit et vend des diagnostics in vitro, des équipements de diagnostic in vit ...
Elisa Oyj est le 1er opérateur de télécommunications finlandais. Le CA par activité se répartit comme suit : - téléphonie mobile (59,2%) ; - prestations de télécommunications fixes (40,8%) : prestations de téléphonie fixe et d'accès à l'Internet haut dé ...
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS est une entreprise basée en Turquie qui se consacre à la recherche, au développement et à la production de diagnostics in vitro. Ses produits de diagnostic comprennent : Microbiologie ...
Bioporto A/S est une société danoise qui développe et commercialise des tests de diagnostic in vitro (DIV). Le portefeuille de la société comprend cinq catégories de produits : Le test NGAL (Neutrophil gelatinase-associated lipocalin), qui permet de diagn ...
Soprocal Calerias e Industrias SA est une société chilienne engagée dans l'acquisition et l'exploitation de gisements minéraux ainsi que dans la production de carbonate de calcium, de chaux vive, de chaux off, de chaux hydraulique, ainsi que d'autres déri ...
Quanterix Corporation est une société spécialisée dans les sciences de la vie. La société développe des plateformes d'immunoessais numériques ultra-sensibles qui font progresser la santé de précision pour la recherche et le diagnostic dans le domaine des ...
AroCell publ AB est une société de diagnostic basée en Suède qui développe des marqueurs pour la détermination de la croissance cellulaire (TK 210) et de l'apoptose. Le principal produit candidat de la société, TK-immuno/hem, est un test de surveillance e ...
Cheilbio Co. est une société coréenne spécialisée dans la fabrication de médicaments vétérinaires. La société propose des antibiotiques, des antimicrobiens, des lactobacilles, des préparations enzymatiques, des parasiticides, des antiseptiques, des oligo- ...
American Vietnamese Biotech Incorporation (AmviBiotech) est une entreprise vietnamienne active dans l'industrie pharmaceutique. La société fabrique des médicaments, des vaccins et des produits biologiques. Elle est également impliquée dans la fabrication ...
Bioventix plc est une société britannique spécialisée dans le développement et la commercialisation d'anticorps monoclonaux à haute affinité pour des applications dans le domaine du diagnostic clinique, telles que les immunodosages automatisés utilisés da ...
Shenzhen Bioeasy Biotechnology Co Ltd est une société chinoise qui se consacre principalement à la recherche, au développement, à la production, à la vente et à la fourniture de produits d'analyse de la sécurité alimentaire et de services connexes. Les pr ...
Aptamer Group plc est une société basée au Royaume-Uni qui développe des liants d'affinité sur mesure grâce à sa plateforme Optimer afin de permettre de nouvelles approches dans les domaines de la thérapeutique, du diagnostic et de la recherche. La platef ...
ViroGates A/S est une entreprise de technologie médicale basée au Danemark. Elle développe une ligne de produits suPARnostic, qui mesure la quantité de protéine soluble urokinase Plasminogen Activator Receptor (suPAR) dans le sang humain. Le niveau de pla ...
Spring Art Holdings Berhad est une société holding d'investissement basée en Malaisie. La société, par l'intermédiaire de sa filiale Spring Art Industries Sdn. Bhd. est principalement impliquée dans la fabrication de produits d'ameublement prêts à assembl ...
Bioqual, Inc. est engagé dans la prestation de services de recherche sous contrat, qui se concentrent sur les modèles in vivo de maladies humaines, y compris le COVID-19, le syndrome d'immunodéficience acquise (SIDA), la grippe, la Mpox, l'infection par l ...
Diadexus, Inc. est une société de diagnostic. La société développe et commercialise des produits qui fournissent aux prestataires de soins de santé des informations pertinentes pour faciliter la prise en charge des patients tout au long de l'évolution de ...
Techlab Inc. (Techlab) est un fabricant d'appareils médicaux de diagnostic. La société développe et fabrique des diagnostics intestinaux dans le monde entier. Techlab fabrique une variété de diagnostics entériques in vitro pour déterminer Clostridium diff ...
Insiders
Elisa Patrizi occupe actuellement le poste de responsable des opérations et de la maintenance chez Infrastrutture Wireless Italiane SpA. Auparavant, Mme Patrizi était directrice du développement sans fil chez Telecom Italia SpA. Elle est titulaire d'un diplôme de premier cycle de l'Universit degli Studi di Roma Tor Vergata.
Francesco Patrizi currently works as a Chief Executive Officer & Director at Società Emiliana Trasporti Autofiloviari S.p.A.
Tony Marco Patrizi is the founder of GR Engineering Services Ltd., a company he founded in 2006.
He currently holds the title of Managing Director & Executive Director at the firm.
In addition to his founding position, Mr. Patrizi has also held former positions.
From 2016 to 2018, he served as an Independent Non-Executive Director at Primary Gold Ltd.
He also worked as an Operations Manager at JR Engineering Services Pty Ltd.
Marco Anselmo Patrizi currently works at Morison KSi Ltd., as Director.
Scott Patrizi is a professional with experience in various non-executive director roles.
He is currently a Non-Executive Director at Forrestania Resources Ltd.
Prior to this, he was the President, Chief Executive Officer & Director at Huntsman Exploration, Inc. from 2021 to 2023.
He also served as a Non-Executive Director at Elixir Energy Ltd.
from 2016 to 2019, and at Rarex Ltd.
from 2016 to 2020.
Additionally, he briefly served as a Non-Executive Director at Caprice Resources Ltd.
in 2021.
Patrizi holds an undergraduate degree from The University of Western Australia Business School.
Elisa currently works at PT Metro Healthcare Indonesia Tbk, as Manager-Finance & Accounting.
Elisa Massimino is a Trustee at the McCain Institute for International Leadership.
Previously, she served as the President & Chief Executive Officer at Human Rights First.
Elisa Coletti is an economist who currently works at Intesa Sanpaolo.
SpA (Broker) as an Economist Banks.
Ms. Elisa Bertolini is a Portfolio Manager at Euromobiliare Asset Management SGR SpA.
She joined Euromobiliare AM Sgr in June 2006.
She graduated with a degree in economics of government and international institutions from the University of Ferrara.
She also has a Masters' Degree in Quantitative Finance and Risk Management from the Bocconi University of Milan
Elisa Burns has been a Trustee at Northern Westchester Hospital Association since 2013.
Dr. Elisa Newby is an Economist at Bank of Finland.
Her current areas of responsibility include preparation of the Bank of Finland’s macroeconomic forecasts and development of forecasting systems and models.
Prior to this she has worked as a lecturer at the University of Cambridge and a researcher at the Centre for Dynamic Macroeconomic Analysis (CDMA) at the University of St Andrews in Scotland.
In 2002–2004, Dr. Newby worked in the Bank of Finland’s Statistics Department, where she was responsible for compiling balance of payments statistics.
In 1999–2002, she served as a derivatives expert on the Helsinki Stock Exchange.
Dr. Newby completed her PhD in Economics at the CDMA in 2007.
Her doctoral dissertation dealt with sustainable monetary policy.
She also has a Master’s degree in Social Sciences from the University of Helsinki.
Elisa DiTommaso has worked as a Director at Heritage Valley Health System, Inc. since 2013.
Elisa Rusu worked at Banca Transilvania SA from 2009 to 2017 as a Manager in the Factoring Department.
Elisa M.
Wilson is currently serving as an Independent Non-Executive Director at GAMCO Investors, Inc. since 2009.
She is also a Director at GGCP, Inc., Associated Capital Group, Inc., and the American Red Cross of Greater New York.
Additionally, she holds positions as a Director at the Breast Cancer Alliance, Member-BPA Board at Brunswick School, Inc., and Trustee at Boston College.
Ms. Wilson has been the President & Trustee of the Gabelli Foundation, Inc. since 2009.
In terms of education, she has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Boston College.
Elisa Perillo worked as a Principal at Umbrella SRL.
She obtained an undergraduate degree from the University of Padua in 2003.
Ms. Elisa Brizuela is a Senior Equity Trader at Segall Bryant & Hamill LLC.
Ms. Brizuela is responsible for Segall Bryant & Hamill's Small Cap Equity trading, as well as assisting institutional equity trading.
She has been in the investment industry since 1987.
Prior to joining the firm, she was an international equity trader at Driehaus Capital Management and William Blair Asset Management.
Elisa Bauchiero served as Director at Aeroporto di Firenze SpA from 2013 to 2014.
She obtained an undergraduate degree from the University of Turku in 1999.
Ms. Elisa Dannemiller is Chief Medical Officer at Sharklet Technologies, Inc. and a Member at American College of Emergency Physicians.
Ms. Dannemiller was previously employed as a Principal by McKinsey & Co., Inc. She also served on the board at The Denver Business Series.
She received her undergraduate degree from the University of Virginia.
Elisa Pascal has a current job as the Head of Shareholder Relations at Edenred SE.
Ms. Elisa Machado is a Senior Economist at ARX Investimentos Ltda.
She was previously employed as Economist by Aria Capital, Economic Consultant by Atico Administração de Recursos Ltda., Economist by Icatu Gestão Patrimonial Ltda., Opus Gestão de Recursos Ltda., FUNCEX - Foreign Trade Studies Center Foundation and Bank of America, Consultnat by CBIE – Brazilian Center of Infrastructure, Researcher by IPEA - Institute for Applied Economic Research and Lecturer by PUC-Rio (1996) and Ibmec (2000).
Ms. Machado holds a degree in Economics from Universidade Federal Fluminense and Master's in Economics from Pontifícia Universidade Católica do Rio de Janeiro.
Elisa Waldeck is a Member of The Institute of Directors, her current job.
In the past, she worked as a Secretary at Blue Financial Services Ltd.
from 2011 to 2012.
Elisa Rizza Trelewicz is currently working as Vice President & Senior Securities Analyst at Columbus Circle Investors since 2001.
She completed her undergraduate degree from the University of Connecticut in 2000.
Elisa Jagerson is a Managing Director at Wildcat where she focuses on investments in Climate Tech SaaS solutions that reduce the effects of climate change.
Her specific areas of interest include AI and Machine Learning (ML) enabled platforms that create disruptive levels of foresight into a future perceived to be unpredictable.
Elisa was most recently CEO of FutureBrand Speck, best known for driving product and service innovation to both market disrupters and industry leaders.
Organizations turned to Elisa and her teams of brand, product, environment and service designers when they needed to accelerate or ‘future proof’ growth.
These products sit today inside our pockets, bodies, hospitals, cars, and data centers, and have generated billions in revenue.
After pioneering ‘experience engineering’, a next generation design thinking methodology credited with infusing reliability into the innovation process, Elisa sold Speck Design to FutureBrand (NYSE: IPG), where she then served on the global leadership team.
Earlier in her career as Founder and CEO of PartsRiver, Elisa pioneered early intelligent data management (IDM) in the transportation industry.
There she acquired $150M in assets from Saqqara and CDC (a Boeing subsidiary), growing PartsRiver into the leading provider of IDM.
Following her success at PartsRiver, Elisa launched and ran Bay Laurel Capital, a micro-cap leveraged buyout firm affiliated with AI LLC.
Elisa began her finance career in global emerging markets, making investments at New York-based private equity firm Zephyr Management and Harare-based ZPF.
Elisa received a BA Cum Laude from Princeton University and an MBA from the Wharton School of Business.
Elisa Dozono currently works as a Director at Oregon Public Broadcasting.
Elisa Weiss currently works as a Director at PearlPoint Cancer Support, Inc.
Elisa Mammi currently works at Decal In Pvt Ltd., as Director & Head-Marketing.
Aucun résultat pour cette recherche
- Bourse
- Recherche avancée
- Elisa Patrizi